Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma is a research paper published in Journal for ImmunoTherapy of Cancer (2025). On theSindex it has a DataRank of 0.401. It has been cited 10 times, with 10 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.360
From this paper's citation signal
Citation Network Contribution
0.0411
From 4 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 10 citers.
Center for Cancer Research
Grant: ZIA BC 011954
National Cancer Institute
Grant: UM1CA154967
National Institutes of Health
Grant: 2UM1CA154967-07
Cancer Immunotherapy Trials Network Central Operations and Statistical Center
National Institutes of Health
Grant: 1ZIABC011954-03
Targeted therapies for Kaposi sarcoma and KSHV-multicentric Castleman disease
FWCI
4.45
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals